Mintz K P, Grzesik W J, Midura R J, Robey P G, Termine J D, Fisher L W
Bone Research Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland.
J Bone Miner Res. 1993 Aug;8(8):985-95. doi: 10.1002/jbmr.5650080812.
Bone sialoprotein (BSP), a small (approximately 80,000 M(r)) integrin binding, RGD-containing bone matrix glycoprotein, has been purified in milligram quantities from the serum-free medium of the rat osteosarcoma cell line UMR-106-BSP using nondenaturing conditions. Routine protein purification without serine protease inhibitors or reducing agents consistently resulted in three major fragments. The largest fragment (E1) started at amino acid 117 and did not bind to antibodies made to the RGD region of the protein. Furthermore, the smallest fragment (E3), was shown by sequencing to contain the RGD region of the protein. Digestion of intact BSP with highly purified chymotrypsin also resulted in a large fragment (C1) with properties nearly identical to those of E1. The large, non-RGD-containing fragments, E1 and C1, as well as the intact BSP, supported attachment by normal human bone cells and human skin fibroblasts in vitro. Attachment to the intact BSP was totally blocked by 0.4 mM GRGDS peptide. Both preparations of skin fibroblasts and approximately half of the preparations of normal human bone cells, however, also would not attach to the E1 and C1 fragments in the presence of 0.4 mM GRGDS peptide. In contrast, half of the bone cell preparations had significant attachment activity to E1 (> 50%) and C1 (> 25%) in the presence of 0.4 mM GRGDS peptide. These data suggest that cleavage of the BSP results in either (1) the exposure of a previously unavailable or cryptic cell attachment site or (2) a conformational change that increases the affinity of the complex between a non-RGD-encoded binding region of the E1 and C1 fragments and at least one receptor. The possible homology of the second, non-RGD-suppressible site of BSP with the second cell attachment site on the gamma chain of fibrinogen is discussed.
骨唾液蛋白(BSP)是一种分子量较小(约80,000 M(r))的整合素结合性、含RGD的骨基质糖蛋白,已在非变性条件下从大鼠骨肉瘤细胞系UMR - 106 - BSP的无血清培养基中纯化出毫克量。在没有丝氨酸蛋白酶抑制剂或还原剂的情况下进行常规蛋白质纯化,始终会产生三个主要片段。最大的片段(E1)起始于第117位氨基酸,不与针对该蛋白RGD区域制备的抗体结合。此外,通过测序显示最小的片段(E3)包含该蛋白的RGD区域。用高度纯化的胰凝乳蛋白酶消化完整的BSP也会产生一个大片段(C1),其性质与E1几乎相同。大的、不含RGD的片段E1和C1以及完整的BSP在体外支持正常人骨细胞和人皮肤成纤维细胞的附着。完整BSP的附着被0.4 mM GRGDS肽完全阻断。然而,在存在0.4 mM GRGDS肽的情况下,皮肤成纤维细胞制剂以及大约一半的正常人骨细胞制剂也不会附着于E1和C1片段。相反,在存在0.4 mM GRGDS肽的情况下,一半的骨细胞制剂对E1(> 50%)和C1(> 25%)具有显著的附着活性。这些数据表明,BSP的裂解导致要么(1)暴露先前不可用或隐蔽的细胞附着位点,要么(2)构象变化,增加了E1和C1片段的非RGD编码结合区域与至少一种受体之间复合物的亲和力。讨论了BSP的第二个非RGD可抑制位点与纤维蛋白原γ链上第二个细胞附着位点可能的同源性。